• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » How Does Ketamine Compare to ECT in Treatment-Resistant Depression?
Research Update

How Does Ketamine Compare to ECT in Treatment-Resistant Depression?

November 9, 2023
Awais Aftab, MD.
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Awais Aftab, MD. Dr. Aftab has no financial relationships with companies related to this material.

Review of: Anand A et al, N Engl J Med 2023;388(25):2315–2325

Study type: Randomized open-label controlled trial

Intravenous ketamine is a promising intervention for treatment-resistant depression, but how does it compare to the gold standard of ECT? When the two were compared head-to-head in study, ECT had higher remission rates (63% vs 46%), but this was not a strictly treatment-resistant sample (Ekstrand J et al, Int J Neuropsychopharmacol 2022;25(5):339–349). The current study compared the two in treatment-resistant depression.

The authors identified 403 patients with non-psychotic, treatment-resistant major depression who had been referred to an ECT clinic. These patients were then randomly assigned to receive either three weeks of ketamine or ECT. Ketamine was delivered twice per week (0.5 mg per kg body weight) and ECT three times a week (beginning as right unilateral, with the option to switch to bilateral if no response). The primary outcome was response, defined as a reduction of ≥50% from baseline on the self-reported Quick Inventory of Depressive Symptomatology. After the initial three-week treatment phase, responders were treated at the discretion of their providers and followed for six months. 

Most were outpatients (89%) with moderate to severe depression that had lasted a median of two years. Most had comorbid psychiatric disorders and were taking antidepressants with or without augmentation agents, 14%–15% had melancholic features, and 39% had attempted suicide. Patients’ mean age was 46, the majority were White (88%), and 51% were women. 

After three weeks of treatment, response rates were higher for ketamine (55% vs 41%; p<0.001). At six months follow-up, relapse rates were lower in the ketamine group (34% vs 56%). Cognitive and musculoskeletal adverse effects were greater with ECT, while dissociation was higher on ketamine. Improvements in quality of life were similar for both groups. 

Several factors may have worked against ECT. Most subjects entered the trial with a preference for ketamine, causing more to drop out when they discovered they were randomized to ECT (31 drop-outs vs four with ketamine). Typical ECT responders were excluded or underrepresented in this study: psychotic depression, catatonic depression, severe or inpatient depression, and older adults. ECT may have been underdosed with six to nine sessions instead of the standard 12 treatments (93% of the study participants received at least six ECT sessions, and 70% received all nine). Although most of the ECT response is observable by six sessions, the abbreviation may have raised the rate of relapse down the road.

Carlat Take

In this large trial, outpatients with treatment-resistant, non-psychotic depression were more likely to get well and stay well with ketamine than ECT. However, ECT remains the treatment of choice for psychotic and catatonic depression and may be more effective for inpatients and older adults.

General Psychiatry Research Update
KEYWORDS depression ECT ketamine mood disorders
    Awais Aftab, MD.

    Ketamine Fails to Outperform Placebo for Depression in Patients Under Anesthesia

    More from this author
    www.thecarlatreport.com
    Issue Date: November 9, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Adult ADHD, TCPR, November/December 2023
    Binge Eating Disorder: Management and Treatment Options
    Adult ADHD Treatment Challenges
    Migraine in the Psychiatric Patient
    How Does Ketamine Compare to ECT in Treatment-Resistant Depression?
    Surprise Result for Adherence in Bipolar Disorder
    Age Matters in Antidepressant Response
    Health Benefits of a Silly Walk
    Mirtazapine Augmentation in OCD
    Can We Predict Suicidal Behaviors by Tracking Dreams?
    CME Post-Test Adult ADHD, TCPR, November/December 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.